Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Chemoradiation in Head and Neck Cancer
NCT01345084Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Nov 2013
- Primary completion
- Nov 2013
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eurofarma. Planned start Nov 2013; status: withdrawn.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01345084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01345084.